Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of chronic or relapsing COVID-19 in immunodeficiency
Li‐An K. Brown, Ed Moran, Anna L. Goodman, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 149, Iss. 2, pp. 557-561.e1
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin Laracy, Miguel-Ángel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 89
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Yu Gao, Curtis Cai, David Wullimann, et al.
Immunity (2022) Vol. 55, Iss. 9, pp. 1732-1746.e5
Open Access | Times Cited: 60
Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”
M. Veronica Dioverti, Sonsoles Salto‐Alejandre, Ghady Haidar
Current Transplantation Reports (2022) Vol. 9, Iss. 4, pp. 209-218
Open Access | Times Cited: 57
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study
Adrian M. Shields, Sian Faustini, Harriet J. Hill, et al.
Journal of Clinical Immunology (2022) Vol. 42, Iss. 5, pp. 923-934
Open Access | Times Cited: 50
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
Federico Baldi, Chiara Dentone, Małgorzata Mikulska, et al.
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 30
Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection
Zeno Pasquini, Alice Toschi, Beatrice Casadei, et al.
Hematological Oncology (2023) Vol. 41, Iss. 5, pp. 904-911
Open Access | Times Cited: 25
Early combination therapy of COVID-19 in high-risk patients
Hans Martin Orth, Charlotte Flasshove, Moritz Berger, et al.
Infection (2023) Vol. 52, Iss. 3, pp. 877-889
Open Access | Times Cited: 22
Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management
Suzy Meijer, Yael Paran, Ana Belkin, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 1012-1017
Closed Access | Times Cited: 11
Respiratory syncytial virus infections in adults: a narrative review
Joanne Wildenbeest, David M. Lowe, Joseph F. Standing, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 10, pp. 822-836
Closed Access | Times Cited: 11
Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review
David Hettle, Stephanie Hutchings, Peter Muir, et al.
Clinical Infection in Practice (2022) Vol. 16, pp. 100210-100210
Open Access | Times Cited: 33
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet)
Giuliana Giardino, Cinzia Milito, Vassilios Lougaris, et al.
Journal of Clinical Immunology (2022) Vol. 42, Iss. 5, pp. 935-946
Open Access | Times Cited: 29
Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity
Stuart G. Tangye, Laurent Abel, Salah Al-Muhsen, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 4, pp. 818-831
Open Access | Times Cited: 29
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
Vinit Upasani, Katie Townsend, Mary Wu, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 950-960
Open Access | Times Cited: 16
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody
Shuhei Maruyama, Daiki Wada, Shuji Kanayama, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy
Yusri Taha, Hayley Wardle, Adam Evans, et al.
Annals of Clinical Microbiology and Antimicrobials (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 33
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
M. Veronica Dioverti, Zeinab El Boghdadly, Zainab Shahid, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 12, pp. 810-821
Open Access | Times Cited: 25
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway
Alessandra D’Abramo, Serena Vita, Gaetano Maffongelli, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 23
Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient Patients
Michele Chan, Me Me Nay Linn, Thomas O’Hagan, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 6, pp. 1083-1092
Open Access | Times Cited: 15
Unveiling COVID‐19 treatment strategies for immunocompromised individuals: Therapeutic innovations and latest findings
Li‐Teh Liu, Jih‐Jin Tsai
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 1
Open Access | Times Cited: 5
Navigating Coronavirus Disease 2019 in Immunocompromised Populations
Majd Alsoubani, Jennifer Chow
Infectious Disease Clinics of North America (2025)
Closed Access
Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors
Jonas Becker, Megan L. Stanifer, Sarah R. Leist, et al.
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 2005-2023
Open Access | Times Cited: 19
Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series
Bianca Maria Longo, Francesco Venuti, Alberto Gaviraghi, et al.
Antibiotics (2023) Vol. 12, Iss. 9, pp. 1460-1460
Open Access | Times Cited: 11
Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab
Tal Brosh‐Nissimov, Nir Ma'aravi, Daniel Leshin-Carmel, et al.
Journal of Microbiology Immunology and Infection (2023) Vol. 57, Iss. 1, pp. 189-194
Open Access | Times Cited: 11
Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report
Serena Vita, Alessandra D’Abramo, Andrea Coppola, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top